Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1.64M
-
Number of holders
-
43
-
Total 13F shares, excl. options
-
8.6M
-
Shares change
-
+884K
-
Total reported value, excl. options
-
$98M
-
Value change
-
+$10.2M
-
Number of buys
-
30
-
Number of sells
-
-9
-
Price
-
$11.40
Significant Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q4 2020
49 filings reported holding LYRA - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value as of Q4 2020.
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) has 43 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.6M shares
.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (3.22M shares), Polaris Venture Management Co. V, L.L.C. (1.1M shares), RA CAPITAL MANAGEMENT, L.P. (816K shares), Ikarian Capital, LLC (815K shares), ArrowMark Colorado Holdings LLC (776K shares), Soleus Capital Management, L.P. (456K shares), BlackRock Inc. (264K shares), JPMORGAN CHASE & CO (191K shares), VANGUARD GROUP INC (174K shares), and BOOTHBAY FUND MANAGEMENT, LLC (87.4K shares).
This table shows the top 43 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.